Purchase this article with an account.
Kiyup Nam, Jung Yeul Kim, Kyung Sup Shin; Comparison between Single Injection and Consecutive Injection of Intravitreal Bevacizumab on Macular Edema in Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):919.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effectiveness of intravitreal bevacizumab for treating macular edema in retinal vein occlusion between single injection and consecutive injection procedures.
The medical records of 56 patients diagnosed with macular edema caused by retinal vein occlusion and treated with intravitreal bevacizumab injection(1.25 mg/0.05 mL) from September 2006 to March 2011 were retrospectively analyzed. Patients with an initial visual acuity <0.5 and central retinal thickness in optical coherence tomography (OCT) >300 μm were treated with intravitreal bevacizumab injection. Patients followed-up for over 6 months were divided into a single-injection group and consecutive-injection group (injection three times with 1-month intervals). If necessary, an additional injection was provided. Changes in visual acuity, decrease in central retinal thickness, and rate of additional injection were compared between the two groups.
Changes in logMAR of the single-injection group were -0.27, -0.28, -0.25, and -0.27 at 1, 2, 3, and 6 months, respectively. Those of the consecutive-injection group were -0.27, -0.35, -0.37, and -0.30, respectively. Although the degree of improvement was greater in the consecutive-injection group, the difference was not statistically significant. Central retinal thickness decreased by 245.7, 244.5, 201.9, and 216.5 μm in the single-injection group at 1, 2, 3, and 6 months, respectively, while that of the consecutive-injection group declined by 294.6, 323.3, 328.7, and 266.0 μm, respectively. The decrease in central retinal thickness was larger in the consecutive-injection group, but the difference was significant only at 3 months. The rate of additional injection was lower in the consecutive-injection group than in the single-injection group (31.8% and 64.7%, respectively; p=0.028).
Improvement in visual acuity and decrease in central retinal thickness at the 6-month follow-up were greater in the consecutive-injection than the single-injection group, but the difference was not statistically significant. The rate of additional injection was significantly lower in the consecutive-injection group.
This PDF is available to Subscribers Only